for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Adamas Pharmaceuticals Inc

ADMS.OQ

Latest Trade

5.49USD

Change

0.05(+0.83%)

Volume

59,451

Today's Range

5.40

 - 

5.61

52 Week Range

3.35

 - 

12.57

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Adamas Pharmaceuticals Files For Mixed Shelf Of Up to $200 Mln

Nov 7 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.

Adamas Pharma Posts Q3 Loss Per Share Of $0.99

Nov 7 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.99.Q3 EARNINGS PER SHARE ESTIMATE $-0.89 -- REFINITIV IBES DATA.Q3 GOCOVRI PRODUCT SALES OF $13.9 MILLION.TOPLINE RESULTS FROM INROADS PHASE 3 STUDY OF ADS-5102 ARE EXPECTED IN SECOND HALF OF DECEMBER 2019.

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer

Sept 13 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS PHARMACEUTICALS APPOINTS NEIL MCFARLANE AS CHIEF EXECUTIVE OFFICER.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY, LEAD INDEPENDENT DIRECTOR, APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE SUCCEEDS GREGORY WENT.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE NAMED CHIEF EXECUTIVE OFFICER & APPOINTED TO ADAMAS BOARD OF DIRECTORS, EFFECTIVE SEPTEMBER 16.ADAMAS PHARMACEUTICALS INC - GREGORY WENT WILL STEP DOWN FROM BOARD OF DIRECTORS AND TRANSITION TO A STRATEGIC ADVISORY ROLE.ADAMAS PHARMACEUTICALS INC - MCFARLANE MOST RECENTLY SERVED AS CHIEF OPERATING OFFICER OF RETROPHIN INC.

Adamas Pharmaceuticals Appoints Neil Mcfarlane As Chief Executive Officer

Sept 13 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS PHARMACEUTICALS APPOINTS NEIL MCFARLANE AS CHIEF EXECUTIVE OFFICER.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY, LEAD INDEPENDENT DIRECTOR, APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - DAVID MAHONEY APPOINTED TO CHAIRMAN OF BOARD.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE SUCCEEDS GREGORY WENT.ADAMAS PHARMACEUTICALS INC - NEIL MCFARLANE NAMED CHIEF EXECUTIVE OFFICER & APPOINTED TO ADAMAS BOARD OF DIRECTORS, EFFECTIVE SEPTEMBER 16.ADAMAS PHARMACEUTICALS INC - GREGORY WENT WILL STEP DOWN FROM BOARD OF DIRECTORS AND TRANSITION TO A STRATEGIC ADVISORY ROLE.ADAMAS PHARMACEUTICALS INC - MCFARLANE MOST RECENTLY SERVED AS CHIEF OPERATING OFFICER OF RETROPHIN INC.

Adamas Reports Q2 Loss Per Share $0.90

Aug 8 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.90.Q2 EARNINGS PER SHARE ESTIMATE $-0.98 -- REFINITIV IBES DATA.ALFRED MERRIWEATHER, CFO, TO RETIRE; CHRIS PRENTISS, SVP FINANCE AND CHIEF ACCOUNTING OFFICER, NAMED AS SUCCESSOR.

Adamas Reports Recent Achievements And Financial Results For The Fourth Quarter And Full-Year 2018

March 4 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS REPORTS RECENT ACHIEVEMENTS AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR 2018.Q4 LOSS PER SHARE $1.06.Q4 EARNINGS PER SHARE ESTIMATE $-1.34 -- REFINITIV IBES DATA.ADAMAS PHARMACEUTICALS - REPORTED GOCOVRI NET PRODUCT SALES OF $13.3 MILLION FOR 3 MONTHS ENDED DEC 31, 2018, VERSUS $0.6 MILLION FOR THREE MONTHS ENDED DEC 31, 2017.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES TO BE BETWEEN $35 MILLION AND $45 MILLION.

Adamas Pharmaceuticals Reports Q3 Loss Per Share $1.22

Nov 1 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $1.22.Q3 EARNINGS PER SHARE VIEW $-1.34 -- THOMSON REUTERS I/B/E/S.Q3 SALES $10.6 MILLION VERSUS I/B/E/S VIEW $10.2 MILLION.ADAMAS ENDED QUARTER WITH $233.2 MILLION OF CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE SECURITIES.

Adamas Pharma And Unit Filed First Amended Answer Against Osmotica Pharma & Vertical Pharma

Sept 24 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS - CO,UNIT FILED FIRST AMENDED ANSWER INCLUDING INFRINGEMENT COUNTERCLAIMS AGAINST OSMOTICA PHARMA & VERTICAL PHARMA- SEC FILING.ADAMAS PHARMACEUTICALS - AMENDED ANSWER INCLUDING INFRINGEMENT COUNTERCLAIMS IN ITS ONGOING LITIGATION CONCERNING OSMOLEX ER IN COURT.ADAMAS PHARMACEUTICALS INC - OSMOTICA FILED A COMPLAINT SEEKING A DECLARATORY JUDGEMENT OF NON-INFRINGEMENT OF MULTIPLE ADAMAS PATENTS.ADAMAS PHARMACEUTICALS INC - ADAMAS' COUNTERCLAIMS ASSERT THAT OSMOTICA HAS INFRINGED NINE ADAMAS PATENTS.

Adamas Pharmaceuticals Q2 Loss Per Share $1.26

Aug 2 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.26.Q2 EARNINGS PER SHARE VIEW $-1.41 -- THOMSON REUTERS I/B/E/S.ADAMAS PHARMACEUTICALS-ENDED QUARTER WITH $256.3 MILLION OF CASH, CASH EQUIVALENTS, AND AVAILABLE-FOR-SALE SECURITIES, COMPARED TO $176.4 MILLION AT DEC 31, 2017.

Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri

April 19 (Reuters) - Adamas Pharmaceuticals Inc <ADMS.O>::ADAMAS ANNOUNCES FINAL RESULTS FROM THE TWO-YEAR PHASE 3 OPEN-LABEL STUDY OF GOCOVRI™ IN PARKINSON’S DISEASE PATIENTS WITH DYSKINESIA.SAYS PATIENTS RECEIVING GOCOVRI EXPERIENCED LONG-TERM DURABILITY FOR UP TO TWO YEARS.SAYS SAFETY PROFILE WAS CONSISTENT WITH PREVIOUSLY-PUBLISHED CONTROLLED PHASE 3 STUDIES.SAYS RESULTS DEMONSTRATED THAT GOCOVRI WAS GENERALLY WELL TOLERATED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up